<DOC>
	<DOCNO>NCT02539225</DOCNO>
	<brief_summary>The main purpose study evaluate effectiveness S-1 oxaliplatin without ramucirumab first line therapy participant metastatic gastric gastroesophageal junction ( GEJ ) adenocarcinoma .</brief_summary>
	<brief_title>A Study Ramucirumab Participants With Gastric Gastroesophageal Junction Adenocarcinoma</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Ramucirumab</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Have histopathologically cytologically confirm diagnosis metastatic gastric GEJ adenocarcinoma . Participants esophageal cancer eligible . Have receive prior firstline systemic therapy gastric GEJ adenocarcinoma ( prior adjuvant neoadjuvant therapy permit ) . Participants whose disease progress &gt; 24 week follow last dose systemic treatment adjuvant/neoadjuvant set eligible . Have measurable nonmeasurable evaluable disease determine use guideline Response Evaluation Criteria Solid Tumors , Version 1.1 ( RECIST v.1.1 ) . Have performance status 0 1 Eastern Cooperative Oncology Group ( ECOG ) scale baseline . Have adequate organ function . Have estimate life expectancy â‰¥12 week judgment investigator . Eligible participant reproductive potential ( sex ) must agree use contraception ( hormonal barrier method ) study period least 6 month last dose study treatment longer require per local regulation . Are willing provide blood sample research purpose . Submission blood sample mandatory participation study unless restrict local regulation ethical review board ( ERBs ) ; submission tumor tissue sample optional . Participants human epidermal growth factor receptor 2 ( HER2 ) positive status determine per local standard . Participants negative test indeterminate result due reason eligible , provided participant eligible treatment direct tumor overexpress HER2 . Have radiation therapy within 14 day prior randomization . Any lesion require palliative radiation previously irradiate consider response assessment . Have document brain metastasis , leptomeningeal disease , uncontrolled spinal cord compression . Have undergone major surgery within 28 day prior randomization . Are currently enrol , discontinue study drug within last 28 day , clinical trial involve investigational product nonapproved use drug device ( study drug use study ) , concurrently enrol type medical research judge scientifically medically compatible study . Participants participate survey observational study eligible participate study . Are pregnant breast feeding . Females childbearing potential must negative serum urine pregnancy test within 7 day prior first dose study treatment . Have prior malignancy . Have condition ( eg , psychological , geographical , medical ) permit compliance study followup procedure suggest participant , investigator 's opinion , appropriate candidate study .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>